Class Action Lawsuit Alert: Bragar Eagel & Squire, P.C. announces MEREO lawsuit.

A class action lawsuit against Mereo BioPharma Group plc (Mereo) has been initiated by Bragar Eagel & Squire, P.C., a respected stockholder rights law firm. The lawsuit, filed in the United States District Court for the Southern District of New York, is on behalf of individuals and entities who purchased or acquired Mereo American Depositary Shares (ADS) between June 5, 2023, and December 26, 2025, which comprises the Class Period. Investors looking to be appointed as lead plaintiff in the case have until April 6, 2026, to apply to the Court.

The crux of the complaint revolves around allegations that the defendants provided investors with misleading information regarding the Phase 3 ORBIT and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Statements made by the defendants about setrusumab’s potential to decrease annualized fracture rates and to achieve statistical significance were deemed false and misleading. The lawsuit asserts that without this crucial information, investors were led to purchase Mereo’s ADS at inflated prices.

The complaint outlines that on December 29, 2025, Mereo released a statement revealing that neither the ORBIT nor the COSMIC Phase 3 studies achieved their primary endpoints of reducing annualized clinical fracture rates compared to the placebo or bisphosphonate control groups, despite showing an improvement in bone mineral density. Subsequently, Mereo’s ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, registering a staggering decline of over 87.7%.

Investors who incurred losses from purchasing or acquiring Mereo shares are encouraged to reach out to Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker or Melissa Fortunato for further information and to discuss their legal rights. Individuals with pertinent information, inquiries, or seeking clarification on the matter can contact Brandon Walker or Melissa Fortunato via email, telephone, or by completing a contact form. It is emphasized that there are no costs or obligations associated with seeking this information.

Bragar Eagel & Squire, P.C., is a well-known law firm with a national presence that focuses on protecting the rights of shareholders. Their initiative to pursue legal action on behalf of individuals and entities impacted by Mereo’s alleged misleading statements underscores their commitment to upholding investor rights and ensuring accountability in the face of potential securities law violations.